[ad_1]
The US-based company announced the latest data on the candidate vaccine. An application has been submitted to the FDA for an emergency use permit.
Moderna, one of the US-based biotech companies continuing studies of the coronavirus vaccine, announced the final results of the candidate vaccine trial.
The company, which will go to the country’s Food and Drug Administration (FDA) and the European Medicines Agency (EMA), an institution of the European Union, to recommend the widespread use of the vaccine, shared two different results.
94.1 PERCENT PROTECTION
According to clinical studies, the vaccine was found to be 94.1 percent effective in protecting people against the coronavirus.
INCREASED TO 100 PERCENT IN SERIOUS CASES
According to the New York Times, the new data also showed that the vaccine was 100 percent effective in preventing severe cases of coronavirus.
APPLICATION FOR EMERGENCY USE
It was noted that the Food and Drug Administration will decide whether Moderna’s mRNA vaccine is safe and effective enough to allow emergency use, based on test data on 30,000 people.
FIRST STUDIES ON DECEMBER 21
Stephane Bancel, CEO of the company, said that if the process goes smoothly and approval is given, the first vaccines can be made on December 21.
Bancel reported that they are on track to produce 20 million doses by the end of December, with 500 million to 1 billion doses in 2021.
TWO DOSES IN ONE MONTH
It was indicated that for the vaccine in question, two doses will be administered to each person, one month apart, so that 20 million doses will be enough for 10 million people.
Moderna is the second vaccine manufacturer to apply for an emergency use permit, after BioNTech, of which US-based Pfizer and Turkish scientists Uğur Şahin and Özlem Türeci are the founding partners. Pfizer and BioNTech applied on November 20.
Uğur Şahin: Returning to normal life will find the next winter ViDEO
